普托馬尼

普托馬尼
臨床資料
商品名（英語：Drug nomenclature）	Dovprela
其他名稱	PA-824
AHFS/Drugs.com	Monograph
MedlinePlus	a619056
核准狀況	美 DailyMed: Pretomanid;
給藥途徑	口服給藥
ATC碼	J04AK08 (WHO) ;
法律規範狀態
法律規範	歐：Rx-only; 美：處方藥（℞-only）;
識別資訊
	IUPAC命名法 (6S)-2-Nitro-6[4-(trifluoromethoxy)benzyl]oxy6,7-dihydro-5H-imidazo[2,1-b] [1,3]oxazine; ;
CAS號	187235-37-6
PubChem CID	456199;
DrugBank	DB05154;
ChemSpider	401693 ;
UNII	2XOI31YC4N;
KEGG	D10722 ;
ChEMBL	ChEMBL227875 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID8041163 ;
化學資訊
化學式	C14H12F3N3O5
摩爾質量	359.26 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F;
	InChI InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1 ; Key:ZLHZLMOSPGACSZ-NSHDSACASA-N ;

普托馬尼（Pretomanid）用於治療影響肺部的多重抗藥性結核病（英語：Multidrug-resistant tuberculosis）^[4]。是一種口服給藥的抗生素^[5]。常與貝達喹啉和利奈唑胺合併使用^[5]。

常見副作用包括周邊神經病變、痤瘡、嘔吐、頭痛、低血糖、腹瀉和肝炎^[4]。其他副作用包括可能骨髓抑制、視神經炎（英語：Optic neuropathy）和QT間期延長（英語：Drug-induced QT prolongation）^[6]。娠期的安全性仍不清楚^[7]。此藥屬於5-硝基咪唑類藥物^[8]。

普托馬尼分別於2019年及2020年在美國及歐洲取得醫療使用許可^[4] ^[5]。名列世界衛生組織基本藥物標準清單^[9]。此藥是由結核病聯盟（英語：TB Alliance）研發^[8] ^[4]。

參考文獻

^ Pretomanid tablet. DailyMed. 15 September 2019 [25 September 2020].
^ Dovprela (previously Pretomanid FGK) EPAR. European Medicines Agency (EMA). 24 March 2020 [25 September 2020]. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ Dovprela Product information. Union Register of medicinal products. [3 March 2023].
^ ^4.0 ^4.1 ^4.2 ^4.3 FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. U.S. Food and Drug Administration (FDA) (新聞稿). 14 August 2019 [28 August 2019]. （原始內容存檔於19 August 2019）. 本文含有此來源中屬於公有領域的內容。
^ ^5.0 ^5.1 ^5.2 Pretomanid FGK EPAR. European Medicines Agency (EMA). 24 March 2020 [25 September 2020]. （原始內容存檔於20 October 2020）. 互聯網檔案館的存檔，存檔日期20 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ Pretomanid Monograph for Professionals. Drugs.com. [29 October 2021] （英語）.
^ Pretomanid Use During Pregnancy. Drugs.com. [29 October 2021] （英語）.
^ ^8.0 ^8.1 Our Pipeline. TB Alliance. [18 April 2019]. （原始內容存檔於7 April 2019）. 互聯網檔案館的存檔，存檔日期7 April 2019.
^ World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. WHO/MHP/HPS/EML/2023.02.

[Pretomanid_FDA_label-1] Pretomanid tablet. DailyMed. 15 September 2019 [25 September 2020].

[Dovprela_EPAR-2] Dovprela (previously Pretomanid FGK) EPAR. European Medicines Agency (EMA). 24 March 2020 [25 September 2020]. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[3] Dovprela Product information. Union Register of medicinal products. [3 March 2023].

[FDA2019-4] 4.0 ^4.1 ^4.2 ^4.3 FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. U.S. Food and Drug Administration (FDA) (新聞稿). 14 August 2019 [28 August 2019]. （原始內容存檔於19 August 2019）. 本文含有此來源中屬於公有領域的內容。

[EPAR2021-5] 5.0 ^5.1 ^5.2 Pretomanid FGK EPAR. European Medicines Agency (EMA). 24 March 2020 [25 September 2020]. （原始內容存檔於20 October 2020）. 互聯網檔案館的存檔，存檔日期20 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[AHFS2021-6] Pretomanid Monograph for Professionals. Drugs.com. [29 October 2021] （英語）.

[7] Pretomanid Use During Pregnancy. Drugs.com. [29 October 2021] （英語）.

[Tb2021-8] 8.0 ^8.1 Our Pipeline. TB Alliance. [18 April 2019]. （原始內容存檔於7 April 2019）. 互聯網檔案館的存檔，存檔日期7 April 2019.

[WHO23rd-9] World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. WHO/MHP/HPS/EML/2023.02.

[2]

[3]

[1]

[4]

[5]

[6]

[7]

[8]

[9]